Unfit people also have the choice of venetoclax as well as obinutuzumab (VO) as frontline therapy. This is based on a section III trial that in contrast VO with ClbO in aged/unfit patients.113 VO was superior in terms of reaction price and progression-free survival, and experienced a equivalent security profile. https://jamesm319gow6.empirewiki.com/user